NMDA Receptor Activity in Neuropsychiatric Disorders

N-Methyl-d-aspartate (NMDA) receptors play a variety of physiologic roles and their proper signaling is essential for cellular homeostasis. Any disruption in this pathway, leading to either enhanced or decreased activity, may result in the manifestation of neuropsychiatric pathologies such as schizophrenia, mood disorders, substance induced psychosis, Huntington’s disease, Alzheimer’s disease, and neuropsychiatric systemic lupus erythematosus. Here, we explore the notion that the overlap in activity of at least one biochemical pathway, the NMDA receptor pathway, may be the link to understanding the overlap in psychotic symptoms between diseases. This review intends to present a broad overview of those neuropsychiatric disorders for which alternations in NMDA receptor activity is prominent thus suggesting that continued direction of pharmaceutical intervention to this pathway may present a viable option for managing symptoms.

[1]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[2]  B. Diamond,et al.  Mutational analysis of an autoantibody: differential binding and pathogenicity , 1994, The Journal of experimental medicine.

[3]  V. Arolt,et al.  Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex , 2003, Psychopharmacology.

[4]  D. Butterfield,et al.  The Glutamatergic System and Alzheimer’s Disease , 2003, CNS drugs.

[5]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[6]  John Hardy,et al.  Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau , 1998, Nature Neuroscience.

[7]  D. Javitt,et al.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.

[8]  Stephen M. Stahl Depression and Bipolar Disorder. Stahl's Essential Psychopharmacology , 2008 .

[9]  J. Cummings,et al.  Huntington's disease. , 1997, The Psychiatric clinics of North America.

[10]  A. Deutch,et al.  Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  P. Reddy,et al.  Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.

[12]  B. Diamond,et al.  Peptide inhibition of glomerular deposition of an anti-DNA antibody. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[14]  B. Volpe,et al.  Cognition and immunity; antibody impairs memory. , 2004, Immunity.

[15]  R. Ho,et al.  Clinical implications of neuropsychiatric systemic lupus erythematosus , 2009 .

[16]  D R Medoff,et al.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.

[17]  Francesca Bosetti,et al.  Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? , 2002, Archives of general psychiatry.

[18]  M. Petri,et al.  Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. , 2011, Seminars in arthritis and rheumatism.

[19]  NMDA Receptor Subunits: Function and Pharmacology , 2007 .

[20]  J. Coyle,et al.  Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. , 1976, Nature.

[21]  C. Correll,et al.  PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .

[22]  Julie Harris,et al.  Reversing EphB2 depletion rescues cognitive functions in Alzheimer model , 2011, Nature.

[23]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[24]  P. Paoletti,et al.  NMDA receptor subunits: function and pharmacology. , 2007, Current opinion in pharmacology.

[25]  H. Praag,et al.  The role of serotonin in schizophrenia , 1995, European Neuropsychopharmacology.

[26]  G. Griebel,et al.  The Glycine Transporter-1 Inhibitor SSR103800 Displays a Selective and Specific Antipsychotic-like Profile in Normal and Transgenic Mice , 2010, Neuropsychopharmacology.

[27]  M. Fava,et al.  Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D , 2008, Journal of General Internal Medicine.

[28]  Carlos A. Zarate,et al.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders , 2008, Nature Reviews Drug Discovery.

[29]  Beate D. Kretschmer,et al.  Modulation of the Mesolimbic Dopamine System by Glutamate , 1999, Journal of neurochemistry.

[30]  R. Malinow New developments on the role of NMDA receptors in Alzheimer's disease , 2012, Current Opinion in Neurobiology.

[31]  J. Lindenmayer New pharmacotherapeutic modalities for negative symptoms in psychosis , 1995, Acta psychiatrica Scandinavica. Supplementum.

[32]  E. Salińska,et al.  N-methyl-d-aspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: in vitro--superfusion study. , 2002, Folia neuropathologica.

[33]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[34]  M. Millan N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives , 2005, Psychopharmacology.

[35]  D. Goff,et al.  Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.

[36]  W. Fleischhacker New drugs for the treatment of schizophrenic patients , 1995, Acta psychiatrica Scandinavica. Supplementum.

[37]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Carlos Cepeda,et al.  Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.

[39]  Alexander Alanine,et al.  Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. , 2010, Journal of medicinal chemistry.

[40]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[41]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[42]  A. Popescu,et al.  Neuropsychiatric Systemic Lupus Erythematosus , 2011, Current neuropharmacology.

[43]  J. Coyle,et al.  Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.

[44]  S. Stahl,et al.  The dopamine hypothesis of schizophrenia: a review. , 1976, Schizophrenia bulletin.

[45]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[46]  S. Pirkola,et al.  Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. , 2013, The Journal of clinical psychiatry.

[47]  M. Travis,et al.  Published by The Royal College of Psychiatrists , 2022 .

[48]  J. Kennedy,et al.  N-methyl-d-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels , 2006, Schizophrenia Research.

[49]  T. Pawełczyk,et al.  [Risk factors of schizophrenia development in patients with amphetamines dependence and psychosis (amphetamine-induced psychosis and schizophrenia), and without psychosis]. , 2012, Psychiatria polska.

[50]  S. Stahl,et al.  Glutamate Neurocircuitry: Theoretical Underpinnings in Schizophrenia , 2012, Front. Pharmacol..

[51]  A. V. Kenny,et al.  Assembly and forward trafficking of NMDA receptors (Review) , 2008, Molecular membrane biology.

[52]  B. Laube,et al.  Formation of NR1/NR2 and NR1/NR3 Heterodimers Constitutes the Initial Step in N-Methyl-D-aspartate Receptor Assembly* , 2008, Journal of Biological Chemistry.

[53]  Antonius M. J. VanDongen,et al.  Biology of the NMDA receptor , 2008 .

[54]  J. Kemp,et al.  NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.

[55]  S. Lechner Glutamate-based therapeutic approaches: inhibitors of glycine transport. , 2006, Current opinion in pharmacology.

[56]  R. Kahn,et al.  The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.

[57]  Lisa Chang,et al.  Chronic Lithium Chloride Administration Attenuates Brain NMDA Receptor-Initiated Signaling via Arachidonic Acid in Unanesthetized Rats , 2006, Neuropsychopharmacology.

[58]  K. Manaye,et al.  Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain , 2006, Brain Research Bulletin.

[59]  J. Tsien,et al.  Memory and the NMDA receptors. , 2009, The New England journal of medicine.

[60]  D. Rosielle,et al.  Psychiatry , 1905, NeuroImage.

[61]  J. Mogensen,et al.  Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests , 2013, Neuroscience Letters.

[62]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[63]  T. Steckler,et al.  NMDA receptors, cognition and schizophrenia – Testing the validity of the NMDA receptor hypofunction hypothesis , 2012, Neuropharmacology.

[64]  D. D’Souza,et al.  Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence , 2012, Neuropsychopharmacology.

[65]  M. Dalva,et al.  EphB Controls NMDA Receptor Function and Synaptic Targeting in a Subunit-Specific Manner , 2011, The Journal of Neuroscience.

[66]  A. Fersht,et al.  Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  K. Gogas Glutamate-based therapeutic approaches: NR2B receptor antagonists. , 2006, Current opinion in pharmacology.

[68]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[69]  B. Diamond,et al.  A novel class of anti-DNA antibodies identified in BALB/c mice , 1991, The Journal of experimental medicine.

[70]  B. Volpe,et al.  Human lupus autoantibodies against NMDA receptors mediate cognitive impairment , 2006, Proceedings of the National Academy of Sciences.